Opdualag (Nivolumab / Relatlimab)

Opdualag is a medicine used to treat melanoma, a type of skin cancer, that has spread or can't be removed with surgery. It is given as an infusion into a vein. It works by taking the brakes off the immune system so it can find and attack cancer cells.

Brand names:Opdualag
Medication

What people taking Opdualag (Nivolumab / Relatlimab) report

Every report comes from a Lived member, sent anonymously.

Have you tried Opdualag (Nivolumab / Relatlimab) for Melanoma?

NameHow it went

About Opdualag (Nivolumab / Relatlimab)

What It's For

Opdualag is a prescription immunotherapy that combines two antibody medicines, nivolumab and relatlimab, in a single infusion. It is approved to treat melanoma, a serious form of skin cancer, when the cancer has spread to other parts of the body (metastatic) or cannot be fully removed with surgery (unresectable). It can be used in adults and in children 12 and older who weigh at least 40 kg (about 88 pounds). Opdualag is one of several first treatment options for advanced melanoma. Nivolumab is also sold on its own as Opdivo, and an oncologist may weigh Opdualag against nivolumab alone or other immunotherapy combinations. Opdualag is not approved as treatment after melanoma has been completely removed by surgery; a large trial in that setting found it worked no better than nivolumab alone.

How It Works

The immune system's T cells can recognize and kill cancer cells, but they have built-in brakes, called checkpoints, that keep them from attacking the body's own tissues. Melanoma can exploit these brakes to switch off the T cells that would otherwise destroy it. Each part of Opdualag releases a different brake. Nivolumab blocks PD-1 (programmed death receptor-1), and relatlimab blocks LAG-3 (lymphocyte activation gene-3), another brake on the same T cells. Releasing both at once activates T cells more than blocking either one alone, which helps them attack the tumor. Opdualag does not kill cancer cells directly, and it works in some people but not others. The same release of the brakes is also why it can turn the immune system against healthy organs.

Dosage & Administration

Opdualag is given at an infusion center or clinic as an intravenous (IV) infusion into a vein, which takes about 30 minutes. It is usually given once every four weeks, at a fixed dose that is the same for adults and for teens who weigh at least 40 kg. Treatment generally continues for as long as the cancer is controlled and side effects remain manageable. The dose is not lowered for side effects; instead, infusions may be paused or stopped permanently, depending on how serious a reaction is. If an appointment is missed, call the care team to reschedule as soon as possible.

Side Effects

The most common side effects are muscle and joint pain, tiredness, rash, itching and diarrhea. Routine blood tests also often show lower red blood cell counts, changes in liver tests and low sodium. Many of these are mild, but in the main trial about a third of people had a serious side effect, and about one in six stopped treatment because of side effects. The most important risk is that the activated immune system attacks healthy organs. This can affect the lungs, bowel, liver, kidneys, skin, heart, nerves, eyes and hormone glands such as the thyroid, pituitary and adrenal glands. These reactions can be severe and occasionally fatal, can appear at any point, and can start even after treatment has ended. Underactive thyroid is the most frequent, affecting about one in six people, and usually needs ongoing thyroid hormone replacement. Contact the cancer care team right away for any new or worsening symptom, such as cough or shortness of breath; diarrhea, bloody or black stools or bad stomach pain; yellow skin or eyes or dark urine; chest pain or a racing or irregular heartbeat; unusual or persistent headaches, extreme tiredness, dizziness or fainting, or unusual thirst; blistering or peeling skin or mouth sores; vision changes or eye pain; or muscle weakness, numbness or confusion. These reactions are usually treated with steroid medicines or hormone replacement, and the care team may pause or stop Opdualag; getting treatment early can keep a reaction from becoming more serious. During an infusion, tell the nurse at once about chills, flushing, itching, trouble breathing or feeling faint.

Interactions & Warnings

Before starting, tell the care team about any autoimmune disease such as Crohn's disease, ulcerative colitis or lupus, a past organ transplant, or a nervous system condition such as myasthenia gravis or Guillain-Barre syndrome. Immunotherapy can flare these conditions or trigger transplant rejection. Anyone who has had, or may later need, a stem cell transplant from a donor should discuss it too, because serious and sometimes fatal transplant complications have occurred with this type of medicine. Opdualag can harm a developing baby. People who can become pregnant should have a pregnancy test before starting, use effective birth control during treatment and for at least 5 months after the last dose, and tell the care team right away about a pregnancy. Breastfeeding is not advised during treatment or for 5 months after the last dose. The prescribing information does not list specific drug interactions, but the care team should still know every medicine and supplement you take. Any other doctor treating you, including in an emergency, should know you are receiving or recently received immunotherapy, since immune side effects can appear during or after treatment.

What to Expect

Imaging scans are repeated during treatment to see whether the cancer is shrinking, stable or growing. Blood tests before infusions check liver, kidney and thyroid function so that immune side effects can be caught early, sometimes before symptoms appear. In the trial that led to approval, people with previously untreated advanced melanoma received either Opdualag or nivolumab alone. With Opdualag, the cancer was held in check for a median of about 10 months, compared with about 5 months with nivolumab alone, and tumors shrank in 43% of people compared with 33%. After four years, about 52% of people on Opdualag were alive compared with about 43% on nivolumab alone, although this survival difference did not reach formal statistical significance. Some people have long-lasting control, while others see the cancer grow despite treatment. Because immune side effects can appear months after the last infusion, staying in contact with the care team and reporting new symptoms remains important after treatment stops.

Questions to Ask Your Doctor

  1. 1.Why is Opdualag a better fit for me than nivolumab alone or another treatment option?
  2. 2.How will we know whether it is working, and how often will I have scans and blood tests?
  3. 3.Which symptoms should I report right away, and who do I call after hours or on weekends?
  4. 4.Do my autoimmune condition, past transplant or other health problems change the risk for me?
  5. 5.How long might treatment continue, and what happens if I need to pause or stop it?

Last reviewed • Oct 2026

Educational content, not medical advice.